Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone

Eleni Efstathiou; John W. Davis; Louis Pisters; Weimin Li; Sijin Wen; Ryan P. McMullin; Michael Gormley; Deborah Ricci; Mark Titus; Anh Hoang; Amado J. Zurita; Nam Phuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Patricia Troncoso; Christopher J. Logothetis

doi:10.1016/j.eururo.2019.05.010

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone

Eleni Efstathiou, John W. Davis, Louis Pisters, Weimin Li, Sijin Wen, Ryan P. McMullin, Michael Gormley, Deborah Ricci, Mark Titus, Anh Hoang, Amado J. Zurita, Nam Phuong Tran, Weimin Peng, Thian Kheoh, Arturo Molina, Patricia Troncoso, Christopher J. Logothetis

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Neoadjuvant therapy with abiraterone acetate + prednisone (AAP) + luteinising hormone-releasing hormone agonist (LHRHa) induced significant cytoreduction associated with a lack of recurrence versus LHRHa, though staging did not differ significantly. This first randomised AAP study in localised high-risk prostate cancer explores response heterogeneity and associated molecular effects to guide further research.

Original language	English (US)
Pages (from-to)	418-424
Number of pages	7
Journal	European urology
Volume	76
Issue number	4
DOIs	https://doi.org/10.1016/j.eururo.2019.05.010
State	Published - Oct 2019

Keywords

Abiraterone acetate
Androgen deprivation therapy
Androgen receptor
Androgen receptor splice variant
Glucocorticoid receptor
High-risk localised prostate cancer
Neoadjuvant
Preoperative
Radical prostatectomy
Tumour volume

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2019.05.010

Fingerprint

Dive into the research topics of 'Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone'. Together they form a unique fingerprint.

Cite this

Efstathiou, E., Davis, J. W., Pisters, L., Li, W., Wen, S., McMullin, R. P., Gormley, M., Ricci, D., Titus, M., Hoang, A., Zurita, A. J., Tran, N. P., Peng, W., Kheoh, T., Molina, A., Troncoso, P., & Logothetis, C. J. (2019). Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. European urology, 76(4), 418-424. https://doi.org/10.1016/j.eururo.2019.05.010

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. / Efstathiou, Eleni; Davis, John W.; Pisters, Louis et al.
In: European urology, Vol. 76, No. 4, 10.2019, p. 418-424.

Research output: Contribution to journal › Article › peer-review

Efstathiou, E, Davis, JW , Pisters, L, Li, W, Wen, S, McMullin, RP, Gormley, M, Ricci, D, Titus, M, Hoang, A, Zurita, AJ, Tran, NP, Peng, W, Kheoh, T, Molina, A, Troncoso, P & Logothetis, CJ 2019, 'Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone', European urology, vol. 76, no. 4, pp. 418-424. https://doi.org/10.1016/j.eururo.2019.05.010

Efstathiou E, Davis JW , Pisters L, Li W, Wen S, McMullin RP et al. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. European urology. 2019 Oct;76(4):418-424. doi: 10.1016/j.eururo.2019.05.010

@article{3cfb49d47bd04ce9b3f272d7b189534a,

title = "Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone",

abstract = "Neoadjuvant therapy with abiraterone acetate + prednisone (AAP) + luteinising hormone-releasing hormone agonist (LHRHa) induced significant cytoreduction associated with a lack of recurrence versus LHRHa, though staging did not differ significantly. This first randomised AAP study in localised high-risk prostate cancer explores response heterogeneity and associated molecular effects to guide further research.",

keywords = "Abiraterone acetate, Androgen deprivation therapy, Androgen receptor, Androgen receptor splice variant, Glucocorticoid receptor, High-risk localised prostate cancer, Neoadjuvant, Preoperative, Radical prostatectomy, Tumour volume",

author = "Eleni Efstathiou and Davis, {John W.} and Louis Pisters and Weimin Li and Sijin Wen and McMullin, {Ryan P.} and Michael Gormley and Deborah Ricci and Mark Titus and Anh Hoang and Zurita, {Amado J.} and Tran, {Nam Phuong} and Weimin Peng and Thian Kheoh and Arturo Molina and Patricia Troncoso and Logothetis, {Christopher J.}",

note = "Funding Information: Funding/Support and role of the sponsor: This study was supported by Prostate Cancer Foundation and Janssen Research & Development . Funding Information: Acknowledgements: The authors thank Pauline Dieringer, Elsa Li-Ning Tapia, and Ina Prokhorova for their contributions to this study. Writing assistance was provided by Shala Thomas, PhD, and Ira Mills, PhD, and was funded by Janssen Global Services, LLC. Funding Information: Funding/Support and role of the sponsor: This study was supported by Prostate Cancer Foundation and Janssen Research & Development. Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = oct,

doi = "10.1016/j.eururo.2019.05.010",

language = "English (US)",

volume = "76",

pages = "418--424",

journal = "European urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Clinical and Biological Characterisation of Localised High-risk Prostate Cancer

T2 - Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone

AU - Efstathiou, Eleni

AU - Davis, John W.

AU - Pisters, Louis

AU - Li, Weimin

AU - Wen, Sijin

AU - McMullin, Ryan P.

AU - Gormley, Michael

AU - Ricci, Deborah

AU - Titus, Mark

AU - Hoang, Anh

AU - Zurita, Amado J.

AU - Tran, Nam Phuong

AU - Peng, Weimin

AU - Kheoh, Thian

AU - Molina, Arturo

AU - Troncoso, Patricia

AU - Logothetis, Christopher J.

N1 - Funding Information: Funding/Support and role of the sponsor: This study was supported by Prostate Cancer Foundation and Janssen Research & Development . Funding Information: Acknowledgements: The authors thank Pauline Dieringer, Elsa Li-Ning Tapia, and Ina Prokhorova for their contributions to this study. Writing assistance was provided by Shala Thomas, PhD, and Ira Mills, PhD, and was funded by Janssen Global Services, LLC. Funding Information: Funding/Support and role of the sponsor: This study was supported by Prostate Cancer Foundation and Janssen Research & Development. Publisher Copyright: © 2019

PY - 2019/10

Y1 - 2019/10

N2 - Neoadjuvant therapy with abiraterone acetate + prednisone (AAP) + luteinising hormone-releasing hormone agonist (LHRHa) induced significant cytoreduction associated with a lack of recurrence versus LHRHa, though staging did not differ significantly. This first randomised AAP study in localised high-risk prostate cancer explores response heterogeneity and associated molecular effects to guide further research.

AB - Neoadjuvant therapy with abiraterone acetate + prednisone (AAP) + luteinising hormone-releasing hormone agonist (LHRHa) induced significant cytoreduction associated with a lack of recurrence versus LHRHa, though staging did not differ significantly. This first randomised AAP study in localised high-risk prostate cancer explores response heterogeneity and associated molecular effects to guide further research.

KW - Abiraterone acetate

KW - Androgen deprivation therapy

KW - Androgen receptor

KW - Androgen receptor splice variant

KW - Glucocorticoid receptor

KW - High-risk localised prostate cancer

KW - Neoadjuvant

KW - Preoperative

KW - Radical prostatectomy

KW - Tumour volume

UR - http://www.scopus.com/inward/record.url?scp=85066442398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066442398&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2019.05.010

DO - 10.1016/j.eururo.2019.05.010

M3 - Article

C2 - 31176622

AN - SCOPUS:85066442398

SN - 0302-2838

VL - 76

SP - 418

EP - 424

JO - European urology

JF - European urology

IS - 4

ER -

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this